Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart bracelets could shave minutes off stroke treatment time

NCT ID NCT06330051

Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests whether a smart bracelet system can help hospitals treat stroke patients faster. The bracelets track where patients are in the emergency room and send alerts if treatment is delayed. The goal is to shorten the time between arrival and life-saving clot-busting therapy. The trial involves over 2,200 patients across multiple hospitals in China.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intelligent bracelet automatic positioning and feedback system (FAST model)
What this could lead to
If effective, this system could help hospitals treat stroke patients faster, potentially reducing brain damage and improving recovery outcomes.
What could go wrong
The trial is testing a process change, not a drug, so benefits depend on hospital staff following the system. Results may vary across different hospitals and regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,219 people

The number who actually took part.

Started

Mar 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Hospitals# 1. Secondary or tertiary public hospitals with an emergency department that receive patients with AIS. 2. Admit at least 50 patients of AIS within 4.5 hours after onset each month. 3. Have the capacity of intravenous thrombolytic therapy or/and endovascular treatment. 4. Voluntarily participate in this research and cooperate with the installation of bluetooth positioning device and the improvement of AIS emergency procedures. 5. Have good cooperation relationship among the department of Neurology, Emergency, Interventional department, Neurosurgery department, Laboratory department and Radiology department. 6. Have ability to establish or participate in the establishment of patient information database and arrange a person responsible for the collection of case information. Patients# Patients who are ≥18 years old are eligible for inclusion if they present with AIS diagnosed by CT and/or MRI, arrive at hospital within 4.5 hours after symptom onset, sign the informed consent form and agree to follow up until 3 months after stroke onset. Exclusion Criteria: Hospitals# 1. Hospital that unable to cooperate and complete the research. 2. Hospitals that are participating in other AIS medical quality improvement projects or related clinical trials. Patients# 1. Patients refuse to sign informed consent and follow up until 3 months after stroke onset. 2. Patients with mild nondisabling stroke (Defined as no measurable neurologic deficit, or NIHSS≤3 with only one of the following isolated symptoms: isolated facial paralysis; mild cortical blindness; mild hemianesthesia; mild hemiataxia.) 3. Life expectancy three-months or less by judgment of the investigator. 4. Participation in any interventional study that may affect the outcome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

Contacts and locations

Locations

  • WuQing People's Hospital

    Tianjin, Tianjin Municipality, 301799, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.